SonoNeu, a biotechnology company co-founded by Sreekanth Chalasani, PhD, has emerged from stealth mode to spearhead a groundbreaking initiative in sonogenetics, a novel modality that utilizes ultrasound to noninvasively control specific cells tagged with ultrasound-sensitive proteins. This project, backed by a significant $41.3 million award from the Advanced Research Projects Agency for Health (ARPA-H), aims to develop therapeutic strategies for debilitating conditions such as peripheral neuropathy through precise modulation of cellular activity.

The implications of this research extend far beyond peripheral conditions. By leveraging sonogenetics, which allows for targeted ultrasound activation of engineered cells, the project envisions a future where therapies can be delivered without the need for invasive procedures or pharmaceuticals. The collaboration involves six leading research institutions, including MIT and Duke University, which will contribute to the development of core biological tools and next-generation ultrasound delivery systems. This multi-institutional effort aims to generate robust preclinical evidence to facilitate a clear regulatory pathway toward FDA evaluation and commercialization.

The advancement of sonogenetics could significantly alter the landscape of therapeutic development in the field of aging and neurology. By providing a drug-free, non-invasive treatment option, this technology has the potential to address a wide array of conditions, including those affecting the central nervous system, such as epilepsy and Parkinson’s disease. The precision offered by sonogenetics may not only enhance therapeutic efficacy but also reduce the risk of side effects associated with traditional treatments, thereby reshaping research paradigms and accelerating timelines for drug development in the longevity sector.

Source: globenewswire.com